BioInvent at a glance

As of September 30, 2025

4
Programs in clinical development
10+
Licensing, supply and collaboration agreements
124
Employees (full time equivalent)
690.5
SEKm in liquid funds etc
Bioinvent - Jefferies Global Healthcare Conference, London

Jefferies Global Healthcare Conference, London

November 18, 2025

Watch video

Listen to the fire side chat with CEO Martin Welschof and the Stifel analyst Oscar Haffen-Lamm

Stifel 2025 Healthcare Conference
November 12, 2025

Listen to

Listen to CEO Martin Welschof at Aktiespararna’s digital Life Science event

October 21, 2025

Watch video

Listen to CSO Björn Frendéus at the BioStock event Investing in Life Science - From Seed to Success

September 23, 2025

Watch video
Björn Frendeus

Interview with CEO Martin Welschof about the narrowed portfolio

Aug 26, 2025

Watch Video

Redeye interviews CEO Martin Welschof and CMO Andres McAllister about BI-1808 in
T-cell lymphoma

Redeye interviews CEO Martin Welschof and CMO Andres McAllister about BI-1808 in T-cell lymphoma.

Watch Video

Interview with CEO Martin Welschof and CMO Andres McAllister

Interview with CEO Martin Welschof and CMO Andres McAllister on the latest data for BI-1206 in solid tumors
June 11, 2025

Watch Video

Interview image

Interview with CEO Martin Welschof and CMO Andres McAllister

May 27, 2025

Watch Video

Interview with CEO Martin Welschof about the Xoma deal

May 27, 2025

Watch Video

Video Interview
Shareprice ticker

BioInvent is in a very attractive position with multiple value drivers

BioInvent has five ongoing clinical programs, where each program has its own individual mechanism of action. In this way, the company is not dependent on the success of one individual program or one single technology. In the Discovery phase, BioInvent applies a stringent process in order to make sure that all of the company’s drug candidates have a smart design and high commercial potential for successful partnering at the optimal time for each project.

The company’s Discovery engine not only generates new drug candidates, it also offers ample opportunity for successful collaborations and partnering.

Stringent portfolio management

All pharmaceutical development is associated with risk. BioInvent manages these risks by a stringent portfolio management, a diversified approach to drug candidates and mechanisms of action, and by targeting a very attractive space in the pharmaceutical landscape. Partnerships within the big pharma community, solid ownership and a strong cash position give BioInvent a solid platform to continue its transformation.

BioInventStories

Mona Welschof

"My main focus is to support the planning and execution of BioInvent’s clinical studies, including coordination and leadership of clinical operations functions, ensuring GCP compliance and providing strategic guidance in clinical development activities..."
Read more
Mona Welschof

BioInventStories

Björn Frendéus

“The principal function of BioInvent’s Science Advisory Board is to give BioInvent a world-leading, cutting-edge, critical scientific review of all our programs. The scope for the advisory board covers all project phases from discovery to clinical development..."
Read more
Björn Frendéus

BioInventStories

Linda Mårtensson

”The balance of scientific independency, strong team spirit and supportive leadership makes the work environment at Bioinvent very positive. At Bioinvent I am constantly offered new, stimulating challenges..."
Read more
Linda Mårtensson

BioInventStories

Sylvie Ryckebusch

"The business development function at BioInvent serves to expand the company’s capabilities by making connections with important players within the pharmaceutical industry and academia. The main objective is to establish fruitful collaborations with partners with complementary resources or expertise to maximize the value of BioInvent research, preclinical, and clinical assets..."
Read more
Sylvie Ryckebusch

BioInventStories

AACR Annual Meeting 2022

"Exciting translational data were presented for BioInvent’s anti-TNFR2 antibody BI-1808, showing similar biomarker correlations in patient samples as observed in the preclinical setting. The poster on BioInvent’s second anti-FcyRIIB antibody BI-1607 reinforces BioInvent’s evidence base that blocking the Fcγ receptor is a key strategy in controlling outcomes in cancer..."
Read more
AACR Annual Meeting 2022
/

Investor Relations contact

BioInvent strives to provide the financial markets with accurate, consistent and relevant information about the company on a regular basis. In the first instance, IR-related issues should be addressed to the Senior Director Investor Relations.

Cecilia Hofvander

Senior Director Investor Relations

046-286 85 50
[email protected]